↓ Skip to main content

A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of…

Overview of attention for article published in BMC Cancer, June 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
19 Mendeley